Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial - Anticoagulation/Antiplatelet Domain (Denmark)
2020-005963-29Phase 3Completed
- Sponsor
- University of Melbourne
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tinzaparin, enoxaparin and dalteparin in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by University of Melbourne. Started Dec 2020; status: completed.
02
Drugs
tinzaparinenoxaparindalteparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005963-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005963-29.